A robust, cross-functional approach to set the strategic direction for pipeline assets and their target indications in the context of an existing portfolio.
How can we help?
Lucid Strategy Consulting is a global consulting practice dedicated to life sciences. We apply critical thinking and extensive domain knowledge to create actionable outputs which help our clients accelerate and amplify the value of medicines and drive sustainable transformation.
We operate across the spectrum of life sciences consulting, bringing deep expertise to cross-functional teams and within clinical, regulatory, medical, access and commercial. We design and deliver transformational change programmes, create future-fit operating models, integrate advanced technologies and support cross-functional teams to develop asset and commercialisation strategies that deliver transformational value.
Ready to amplify the value of your medicines?
Ready to amplify the value of your medicines?
What we’ll unlock together
Lucid Strategy Consulting operates across the spectrum of life sciences consulting, from:
We apply analytical rigour and domain expertise to the design and delivery of future-fit operating models and sustainable transformation, reducing complexity, aligning functions and driving long-term value.
We help life sciences leaders define and execute integrated strategies that enhance asset and portfolio value, optimise lifecycle performance and align commercialisation strategy and planning with actionable solutions.
We support life sciences organisations in building scalable data and technology solutions, advancing AI adoption, modernising architectures and navigating partner ecosystems to unlock smarter decision-making and sustained innovation.
Explore our core Strategy Consulting capabilities
- Future-fit operating model strategy, design and implementation
- Agile organisation design and implementation
- Process design and optimisation
- Program design and management, business cases, stakeholder engagement and change enablement
- Market, asset and portfolio evaluation
- Early asset strategy and value proposition
- Asset and portfolio lifecycle strategy
- Launch excellence, strategy and planning
- Integrated strategic planning including strategic brand planning, IEGP, market penetration etc.
- Above-molecule value proposition
- Technology and data architectures and solutions
- Market landscape and partner selection
- AI strategy, governance, use case definition, adoption
Are you ready to drive sustainable transformation in your organisation?
Are you ready to drive sustainable transformation in your organisation?
Explore our capabilities
Explore how our core capabilities, enabled by AI and advanced analytics, work together to drive belief, accelerate adoption, and create the momentum your brand needs to lead.
Explore our Strategy Consulting case studies
Explore our Strategy Consulting case studies
Global evidence generation strategy
Global evidence generation strategy
Development of an evidence-generation strategy and expanded LCM opportunities to drive competitive differentiation aligned to stakeholder market-value drivers.
See case study
Accelerating the pathway to launch for a breakthrough oncology asset
Accelerating the pathway to launch for a breakthrough oncology asset
Our client needed a partner to help them navigate the journey to launch and successfully bring their product to market while creating a model for future launches across the organisation.
See case study
Portfolio buy and build
Portfolio buy and build
A thorough process to assess and validate future development and acquisition targets, optimising portfolio and disease area strategy and aligning key stakeholders to plan.
See case study
Outsourcing strategy for scalable growth
Outsourcing strategy for scalable growth
Target Clinical Development outsourcing operating model.
See case study
Digitising Medical planning
Digitising Medical planning
Digitising of Global oncology Medical strategy plans across assets.
See case study
Explore our Strategy Consulting white papers
Explore our Strategy Consulting white papers
DCTs: achieving our ambition
DCTs: achieving our ambition
Decentralised clinical trials (DCTs) present a biopharmaceutical company with a series of opportunities and challenges. We highlight the challenges and examine...
See article and view paper
Medical operations of the future
Medical operations of the future
As Medical Affairs organisations continue to evolve, the 'Medical Operations' or 'Medical Excellence' group is becoming increasingly important. This paper explores how Medical Operations groups can best evolve to...
See article and view paper
Medical Affairs KPIs
Medical Affairs KPIs
The purpose of this paper is to describe how effective Medical Affairs KPIs can be developed as straightforwardly as possible, and to present key elements that organisations should consider in their own KPI dashboards.